Gossamer Bio, Inc. GOSS
10.94
0.01
0.09%
as of 25 Sep
- Market cap
- $66.8M
- P/E
- 0.0×
Follow GOSS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 178.72% | 215.10% | 365.33% | 1,107.65% |
+8 more TTM periods Free account |
|
| (78.81%) | (88.11%) | (69.89%) | (55.80%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
192.64% | (264.94%) | (163.39%) | (110.02%) | |
Average Days of Receivables |
41.82 | 60.81 | 92.07 | 76.59 | |
Free Cash Flow per Share |
(40.65) | (58.18) | (59.98) | (55.66) | |
Free Cash Flow |
(162.63) | (170.26) | (171.34) | (158.61) | |
Capital Expenditures |
— | — | (0.08) | (0.18) | |
Piotroski F-Score |
2.00 | 1.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
18,954.08% | (124.74%) | (80.53%) | (53.50%) | |
Accounts Receivable Turnover |
7.79 | 7.01 | 5.52 | 5.57 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.02) | |
Research and Development Expense of Revenue |
307.71% | 322.54% | 359.17% | 366.10% | |
Selling, General and Administrative Expense of Revenue |
89.97% | 85.92% | 77.64% | 82.00% | |
Share Based Compensation of Revenue |
26.89% | 26.03% | 21.78% | 28.65% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.30 | 0.94 | 1.01 | 1.01 | |
Depreciation/Fixed assets |
53.11 | (57.29) | (82.67) | (96.26) | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.03 | |
Revenue per Share |
13.32 | 18.98 | 16.97 | 15.46 | |
Operating CF per Share |
(40.65) | (58.18) | (59.96) | (55.59) | |
Capex per Share |
0.00 | 0.00 | (0.03) | (0.06) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(235.00%) | (324.82%) | (351.49%) | (354.50%) |
Columns are period end dates